Dashboard
Manage Tickers

ANTXAN2 Therapeutics, Inc.


$ 1.04 $ 0.01 (0.96 %)    

Monday, 16-Sep-2024 15:54:00 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.14 $ -2.10 (-0.44 %)
DIA $ 417.33 $ 2.44 (0.59 %)
SPY $ 562.48 $ 0.83 (0.15 %)
TLT $ 101.29 $ 0.92 (0.92 %)
GLD $ 238.61 $ -0.02 (-0.01 %)
$ 1.05
$ 1.04 x 300
-- x --
-- - --
$ 0.87 - $ 22.22
170,978
na
31.33M
$ 1.59
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

an2-therapeutics-adopts-limited-duration-stockholder-rights-plan-which-is-scheduled-to-expire-on-august-15-2025
AN2 Therapeutics Adopts Limited Duration S...
08/16/2024 11:04:22

The Company recently became aware of the rapid accumulation of a significant amount (19.3%) of the common stock of the Company ...

citizens-and-2-other-penny-stocks-insiders-are-buying
Citizens And 2 Other Penny Stocks Insiders...
08/15/2024 11:23:19

an2-therapeutics-q2-eps-048-beats-059-estimate
AN2 Therapeutics Q2 EPS $(0.48) Beats $(0....
08/13/2024 20:05:08

AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0....

crude-oil-rises-blend-labs-shares-jump-following-q2-results
Crude Oil Rises; Blend Labs Shares Jump Fo...
08/09/2024 18:38:50

us-stocks-edge-lower-echostar-shares-tumble-after-q2-results
US Stocks Edge Lower; EchoStar Shares Tumb...
08/09/2024 16:29:02

lung-disease-focused-an2-therapeutics-lackluster-data-prompts-to-stop-phase-3-study-of-lung-infection-candidate-halves-workforce
Lung Disease Focused AN2 Therapeutics' Lac...
08/09/2024 16:15:53

AN2 Therapeutics reported topline results from the Phase 2/3 EBO-301 study of epetraborole in treatment-refractory MAC lung dis...

jmp-securities-maintains-market-outperform-on-an2-therapeutics-lowers-price-target-to-3
JMP Securities Maintains Market Outperform...
08/09/2024 11:00:42

JMP Securities analyst Roy Buchanan maintains AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform and lowers the price t...

an2-therapeutics-announces-update-on-ebo-301-phase-23-study-evaluating-epetraborole-for-treatment-refractory-mycobacterium-avium-complex-lung-disease-study-to-be-discontinued-following-topline-results
AN2 Therapeutics Announces Update On EBO-3...
08/08/2024 21:37:47

EBO-301 study to be discontinued following topline results from Phase 2 part of the study in treatment-refractory patients with...

leerink-partners-upgrades-an2-therapeutics-to-outperform
Leerink Partners Upgrades AN2 Therapeutics...
07/03/2024 18:21:47

Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform.

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
06/14/2024 20:31:12

evercore-isi-group-maintains-in-line-on-an2-therapeutics-lowers-price-target-to-2
Evercore ISI Group Maintains In-Line on AN...
05/16/2024 15:51:38

Evercore ISI Group analyst Liisa Bayko maintains AN2 Therapeutics (NASDAQ:ANTX) with a In-Line and lowers the price target f...

12-health-care-stocks-moving-in-thursdays-after-market-session
12 Health Care Stocks Moving In Thursday's...
04/04/2024 20:31:22

jmp-securities-upgrades-an2-therapeutics-to-market-outperform-announces-6-price-target
JMP Securities Upgrades AN2 Therapeutics t...
04/02/2024 18:05:44

JMP Securities analyst Roy Buchanan upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Market Outperform and ann...

oppenheimer-reiterates-perform-on-an2-therapeuticsto-perform
Oppenheimer Reiterates Perform on AN2 Ther...
04/01/2024 13:13:18

Oppenheimer analyst Jeff Jones reiterates AN2 Therapeutics (NASDAQ:ANTX) from Perform to Perform.

an2-therapeutics-q4-eps-057-beats-076-estimate
AN2 Therapeutics Q4 EPS $(0.57) Beats $(0....
03/28/2024 20:49:43

AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0....

zoominfo-technologies-to-rally-around-50-here-are-10-top-analyst-forecasts-for-tuesday
ZoomInfo Technologies To Rally Around 50%?...
02/13/2024 13:08:24

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

leerink-partners-downgrades-an2-therapeutics-to-market-perform-lowers-price-target-to-7
Leerink Partners Downgrades AN2 Therapeuti...
02/13/2024 12:40:35

Leerink Partners analyst Joseph Schwartz downgrades AN2 Therapeutics (NASDAQ:ANTX) from Outperform to Market Perform and low...

nasdaq-edges-lower-contextlogic-shares-surge
Nasdaq Edges Lower; ContextLogic Shares Surge
02/12/2024 19:15:26

U.S. stocks traded mostly higher toward the end of trading, while the Nasdaq Composite moved slightly lower on Monday. The Dow...

why-big-lots-shares-are-trading-lower-by-around-31-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Big Lots Shares Are Trading Lower By A...
02/12/2024 18:07:28

Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarte...

evercore-isi-group-downgrades-an2-therapeutics-to-in-line-lowers-price-target-to-7
Evercore ISI Group Downgrades AN2 Therapeu...
02/12/2024 17:54:03

Evercore ISI Group analyst Liisa Bayko downgrades AN2 Therapeutics (NASDAQ:ANTX) from Outperform to In-Line and lowers the p...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION